<DOC>
	<DOCNO>NCT02044471</DOCNO>
	<brief_summary>Continuous-flow ( CF ) leave ventricular assist device ( LVADs ) important tool treatment end-stage heart failure , afford patient significantly improve quantity quality life . In recent year , tens thousand LVADs implant worldwide , nearly 1,000 Texas Heart Institute ( THI ) . Despite benefit LVAD therapy , one major weakness high frequency late stroke , report 19 % . CF LVADs minimize remove pulsatility within blood system , introduce new incompletely understood physiology . Increased sympathetic ( `` fight flight '' nervous system ) tone secondary lack pulse blood system cause high blood pressure , subsequent hemorrhaging stroke ( bleed brain ) one possible explanation high adverse event rate CF LVAD patient . A simple intervention decrease increase sympathetic tone call `` ischemic conditioning '' ; sphygmomanometer ( blood pressure cuff ) place patient 's arm compress major artery ( ischemia ) subsequent release cuff ( reperfusion ) set period time . This show reduce blood pressure major adverse cardiovascular event patient population . We plan conduct trial evaluate intervention , ischemic conditioning , patient CF LVADs . We hypothesize IC cause reduction blood pressure stroke patient population .</brief_summary>
	<brief_title>The IMPULSE Study : Pilot</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>continuous flow LVAD able provide inform consent comply followup &lt; 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>leave ventricular assist device</keyword>
	<keyword>continuous flow</keyword>
	<keyword>remote ischemic conditioning</keyword>
	<keyword>hypertension</keyword>
	<keyword>sympathetic tone</keyword>
	<keyword>endothelial dysfunction</keyword>
</DOC>